Prosecution Insights
Last updated: May 29, 2026

Dickinson Wright, PLLC

17 pending office actions • 6 clients • 15 examiners • 8 art units • 0 of 17 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days

Portfolio Summary

17
Total Pending OAs
7
Non-Final OAs
10
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
1
Due this week
5
Due this month
2
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)Due ≤ 7 days (1)Due ≤ 30 days (5)Due ≤ 60 days (2)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
12
Medium (71%)
2
Easy (12%)
3
Unknown (18%)

Rejection Statute Mix

BucketCases
§103 only9 (53%)
§102 only3 (18%)
§112 only2 (12%)
No statute on record3 (18%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

17
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

170 h
Manual time on pending OAs
34 h
Time saved (low, 20%)
59 h
Time saved (mid, 35%)
1.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GOLDBERG, JEANINE ANNE 2 46.0% +40.4%
LAFAVE, ELIZABETH ROSE 2 55.3% +56.3%
PIHONAK, SARAH 1 60.9% +43.4%
KOVACH, KARA NICOLE 1 100.0% +0.0%
WORSHAM, JESSICA N 1 56.6% +57.0%
WOOLWINE, SAMUEL C 1 61.0% +20.0%
HAVLIN, ROBERT H 1 52.3% +27.2%
PARISI, JESSICA DANIELLE 1 79.8% +28.0%
WILDER, CYNTHIA B 1 70.9% +26.6%
LU, FRANK WEI MIN 1 63.0% +66.3%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18549884 CHEMICAL SAMPLE INDEXING FOR HIGH-THROUGHPUT SINGLE-CELL ANALYSIS KOVACH, KARA NICOLE 7d

Interview Candidates (11)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17996196 A METHOD FOR DETECTION OF WHOLE TRANSCRIPTOME IN SINGLE CELLS PARISI, JESSICA DANIELLE 126d overdue
17751023 METHODS AND SYSTEMS FOR DETERMINING CELL-CELL INTERACTION LAFAVE, ELIZABETH ROSE 121d overdue
17957386 SELECTIVE EXTENSION IN SINGLE CELL WHOLE TRANSCRIPTOME ANALYSIS WILDER, CYNTHIA B 42d overdue
18251528 MULTIPLEX DETECTION OF BACTERIAL RESPIRATORY PATHOGENS GOLDBERG, JEANINE ANNE 28d overdue
18568160 EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER PIHONAK, SARAH 26d overdue
17923506 COMPOSITIONS AND METHODS FOR MODIFYING POLYMERASE-NUCLEIC ACID COMPLEXES LAFAVE, ELIZABETH ROSE 15d
18261213 PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB WORSHAM, JESSICA N 27d
18187488 OLIGONUCLEOTIDES ASSOCIATED WITH ANTIBODIES WOOLWINE, SAMUEL C 41d

Client Portfolio (6 clients)

Top Art Units

Art UnitApps
16845
16814
16823
16271
16151
16261
16831
16351

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18568160 EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER Natco Pharma Limited PIHONAK, SARAH 1627 §103 Non-Final OA 26d overdue Pending Dec 07, 2023
18549884 CHEMICAL SAMPLE INDEXING FOR HIGH-THROUGHPUT SINGLE-CELL ANALYSIS Singleron (Nanjing) Biotechnologies, Ltd. KOVACH, KARA NICOLE 1681 §103 Non-Final OA 7d Pending Sep 08, 2023
18261213 PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB Natco Pharma Limited WORSHAM, JESSICA N 1615 Other Final Rejection 27d Pending Jul 12, 2023
18251528 MULTIPLEX DETECTION OF BACTERIAL RESPIRATORY PATHOGENS BECTON, DICKINSON AND COMPANY GOLDBERG, JEANINE ANNE 1682 §103 Non-Final OA 28d overdue Pending May 02, 2023
18251147 A METHOD FOR SINGLE-CELL NASCENT RNA LABELING AND SEQUENCING Singleron (Nanjing) Biotechnologies, Ltd. GOLDBERG, JEANINE ANNE 1682 §103 Final Rejection 61d Pending Apr 28, 2023
18187488 OLIGONUCLEOTIDES ASSOCIATED WITH ANTIBODIES BECTON, DICKINSON AND COMPANY WOOLWINE, SAMUEL C 1681 §112 Final Rejection 41d Pending Mar 21, 2023
18058216 METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING BECTON, DICKINSON AND COMPANY HAVLIN, ROBERT H 1626 Other Final Rejection 54d Pending Nov 22, 2022
17923506 COMPOSITIONS AND METHODS FOR MODIFYING POLYMERASE-NUCLEIC ACID COMPLEXES Pacific Biosciences of California, Inc. LAFAVE, ELIZABETH ROSE 1684 §102 Non-Final OA 15d Pending Nov 04, 2022
17996196 A METHOD FOR DETECTION OF WHOLE TRANSCRIPTOME IN SINGLE CELLS Singleron (Nanjing) Biotechnologies, Ltd. PARISI, JESSICA DANIELLE 1684 §103 Non-Final OA 126d overdue Pending Oct 13, 2022
17957386 SELECTIVE EXTENSION IN SINGLE CELL WHOLE TRANSCRIPTOME ANALYSIS BECTON, DICKINSON AND COMPANY WILDER, CYNTHIA B 1681 §103 Final Rejection 42d overdue Pending Sep 30, 2022
17822948 MEASUREMENT OF PROTEIN EXPRESSION USING REAGENTS WITH BARCODED OLIGONUCLEOTIDE SEQUENCES BECTON, DICKINSON AND COMPANY LU, FRANK WEI MIN 1683 §112 Non-Final OA 71d Pending Aug 29, 2022
17751023 METHODS AND SYSTEMS FOR DETERMINING CELL-CELL INTERACTION Singleron Biotechnologies Inc. LAFAVE, ELIZABETH ROSE 1684 §102 Non-Final OA 121d overdue Pending May 23, 2022
17575094 SURFACE STRUCTURING WITH COLLOIDAL ASSEMBLY Pacific Biosciences of California, Inc. FLINDERS, JEREMY C 1684 §102 Final Rejection 31d overdue Pending Jan 13, 2022
17373653 cDNA SPIKE-IN CONTROL FOR SINGLE CELL ANALYSIS BECTON, DICKINSON AND COMPANY YU, TIAN NMN 1681 §103 Final Rejection 51d overdue Pending Jul 12, 2021
17174249 INTRACELLULAR ABSEQ BECTON, DICKINSON AND COMPANY SHIN, DANA H 1635 §103 Final Rejection 9d Pending Feb 11, 2021
17151058 METHODS AND COMPOSITIONS FOR SINGLE CELL SECRETOMICS BECTON, DICKINSON AND COMPANY SISSON, BRADLEY L 1682 Other Final Rejection 14d Pending Jan 15, 2021
16551620 SAMPLE MULTIPLEXING USING CARBOHYDRATE-BINDING AND MEMBRANE-PERMEABLE REAGENTS Cellular Research, Inc. BUNKER, AMY M 1684 §103 Final Rejection 19d Pending Aug 26, 2019

Managing Dickinson Wright, PLLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month